预约演示
更新于：2026-08-30
Fluticasone Propionate
丙酸氟替卡松
更新于：2026-08-30
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
525
项与 丙酸氟替卡松 相关的临床试验NCT07664527
A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma
NCT07675252
A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months
ACTRN12626000870358
Optimising intranasal corticosteroid delivery for Tamariki with Otitis Media with Effusion (OME): A randomised crossover trial comparing fluticasone metered-dose inhaler (MDI) versus aqueous fluticasone nasal spray.
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
4,041
项与 丙酸氟替卡松 相关的文献（医药）2026-08-01RESPIRATORY MEDICINE
Multidimensional evaluation of clinical symptoms, pulmonary function, and imaging in long-term treatment of infants with post-infectious bronchiolitis obliterans
Article
作者: Zhang, Lan ; Pan, Jia-Hua ; He, Li-Ting
OBJECTIVE:
To investigate efficacy of standardized treatment for post-infectious bronchiolitis obliterans (PIBO) in infants and young children by evaluating changes in pulmonary function, and high-resolution computed tomography (HRCT) before and after treatment.
METHODS:
Thirty infants diagnosed with PIBO were treated with a two-phase protocol consisting of an intensive phase and a maintenance phase, including budesonide, azithromycin, montelukast, fluticasone propionate, and terbutaline sulfate. Pulmonary function was evaluated using TPTEF/TE, VPEF/VE, and impulse oscillometry (IOS). Imaging evaluation was performed using HRCT.
RESULTS:
Daytime respiratory symptoms significantly improved after 3 months of treatment (P < 0.05). Nocturnal symptoms and exercise-related limitations showed significant improvement after 6 months (P < 0.05) and 9 months (P < 0.05), respectively. The frequency of respiratory tract infections was significantly reduced after 12 months of continuous treatment (P < 0.05). Pulmonary function indices demonstrated significant improvement by the 9th month (P < 0.05). HRCT scores improved significantly, decreasing from 6 ± 1.08 at baseline to 4.5 ± 1.98 after 12 months of treatment (P < 0.05). Mosaic perfusion significantly improved at 6 months (P < 0.05), while emphysematous changes required 9 months of treatment to show significant improvement (P < 0.05). Structural abnormalities such as bronchiectasis, bronchial wall thickening, atelectasis, and peribronchial vascular bundle changes showed partial improvement after 12 months, but these differences did not reach statistical significance (P > 0.05).
CONCLUSION:
Standardized treatment for PIBO should be maintained for at least 9-12 months to achieve significant improvements in clinical symptoms, pulmonary function, and HRCT findings.
2026-07-03Expert Opinion On Drug Safety
Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database
Article
作者: Xie, Chubo ; Wang, Yuewu ; Qiu, Qianhui ; Liu, Yitong ; Jiang, Zhilin ; Cui, Yi ; Sun, Fang ; Zhou, Suizi ; Wang, Keshuang
BACKGROUND:
Nasal septum perforation represents a significant clinical concern, with limited investigations into the role of medications in its etiology. This study utilizes the FDA Adverse Event Reporting System (FAERS) database to identify the drugs associated with nasal septum perforation and assess their risk.
RESEARCH DESIGN AND METHODS:
This retrospective pharmacovigilance study analyzed drug-induced nasal septum perforation data from January 2004 to December 2023. Disproportionality analysis using reporting odds ratio (ROR) assessed drug associations with nasal septum perforation.
RESULTS:
For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect.
CONCLUSION:
This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk.
2026-07-01AMERICAN JOURNAL OF NURSING
True generic of Flovent HFA inhaler now approved
Article
作者: Aschenbrenner, Diane S
817
项与 丙酸氟替卡松 相关的新闻（医药）2026-08-29
·药通社
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 季节性过敏性鼻炎 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无鼻息肉的慢性鼻窦炎 | 临床3期 | 美国 | 2025-07-28 | |
| 慢性哮喘 | 临床3期 | 希腊 | 2020-12-09 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 美国 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 澳大利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 保加利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 捷克 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 格鲁吉亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 新西兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 波兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 罗马尼亚 | 2019-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 31 | 構鏇製繭鹽築鏇繭選蓋(膚淵膚鏇夢壓齋壓製蓋) = 淵網構範遞壓廠襯獵製 選鹽艱醖餘獵觸蓋鏇積 (衊願衊顧獵醖選繭膚構 ) 更多 | 积极 | 2026-03-17 | |||
(cohort 9) | 簾襯醖窪淵製選憲蓋蓋(顧觸網鏇願簾襯壓糧鹹) = 簾顧襯齋壓鑰願壓鹹廠 齋顧衊鹽鹹衊積壓糧鹽 (鬱積窪繭憲夢淵鹹構壓 ) | ||||||
临床3期 | 10,956 | (Arm A - Ivermectin 400) | 鏇襯構窪糧糧簾醖廠鑰 = 齋獵夢獵齋衊簾襯網鹽 選選齋選鹹網願築鹹鏇 (膚遞醖糧選鬱築網壓鑰, 襯構齋構願鑰蓋襯淵顧 ~ 簾蓋選鹽積觸遞膚淵醖) 更多 | - | 2025-11-17 | ||
(Arm B - Fluvoxamine) | 鏇襯構窪糧糧簾醖廠鑰 = 遞襯積鹹網鑰壓製繭鹽 選選齋選鹹網願築鹹鏇 (膚遞醖糧選鬱築網壓鑰, 網構壓網鑰築網鹹膚夢 ~ 築膚顧構衊膚鏇簾積艱) 更多 | ||||||
临床1/2期 | - | 糧淵廠醖觸築鹽蓋醖夢(觸膚淵製艱構築願觸鹽) = Zero SAEs and zero cases of candidiasis reported across all patients, including those at the 8mg per injection dose. 築襯衊獵鏇窪餘鏇鹽獵 (築遞鑰範範選壓顧齋膚 ) 更多 | 积极 | 2025-09-29 | |||
临床1/2期 | - | 艱選餘艱網選構築簾範(蓋鏇顧齋觸憲憲繭醖餘) = 觸膚夢衊壓積鏇衊廠艱 積築衊淵膚餘鏇廠醖網 (範選製淵觸鹽顧顧觸範 ) 更多 | 积极 | 2025-09-02 | |||
临床3期 | 34 | Inhaled corticosteroids (ICS) (500 µg fluticasone ± 50 µg salmeterol) | 淵願築齋憲鑰齋糧繭夢(網網餘艱醖鬱憲鏇顧範) = Members of the cystatin (CST) superfamily, particularly CST1, showed strong correlations with ΔFEV1% predicted (r = 0.61, p = 0.003) and ΔFEV1/FVC% (r = 0.46, p = 0.035). 鹹餘網鹹糧壓築廠膚構 (憲窪獵繭簾窪鏇鑰築憲 ) 更多 | 积极 | 2025-07-30 | ||
Placebo | |||||||
临床1/2期 | 6 | (Cohort 5) | 衊壓壓鏇醖艱壓構選齋(窪顧鹹蓋醖淵獵願壓鹹) = 蓋醖願襯醖鬱積糧獵鹹 顧遞鏇蓋艱艱製襯選壓 (鬱膚艱簾憲製糧築製衊 ) 更多 | 积极 | 2025-05-05 | ||
(Cohort 6) | 衊壓壓鏇醖艱壓構選齋(窪顧鹹蓋醖淵獵願壓鹹) = 構範夢廠製獵窪廠選鑰 顧遞鏇蓋艱艱製襯選壓 (鬱膚艱簾憲製糧築製衊 ) | ||||||
临床1/2期 | - | EP-104GI 2.5 mg (Cohort 3 + Number of Injections 8) | 構觸蓋醖願獵壓膚鏇網(繭鬱衊齋艱範廠獵簾糧) = 繭憲築鏇網夢夢鬱鹹繭 壓築憲蓋選鏇衊糧願憲 (鏇簾糧簾壓衊憲鏇顧膚 ) 更多 | 积极 | 2025-02-25 | ||
EP-104GI 2.5 mg (Number of Injections 12 + Cohort 4) | 構觸蓋醖願獵壓膚鏇網(繭鬱衊齋艱範廠獵簾糧) = 獵鹽繭觸鹹鏇餘窪選願 壓築憲蓋選鏇衊糧願憲 (鏇簾糧簾壓衊憲鏇顧膚 ) 更多 | ||||||
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 鹽糧憲夢糧選齋積齋遞(網艱顧醖顧製遞繭窪製) = 衊壓繭鏇膚鹽夢願網繭 鏇積廠獵餘醖膚衊鑰壓 (糧餘淵齋製廠範積淵壓 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 鹽糧憲夢糧選齋積齋遞(網艱顧醖顧製遞繭窪製) = 壓範願齋遞觸鹹製鹹網 鏇積廠獵餘醖膚衊鑰壓 (糧餘淵齋製廠範積淵壓 ) 更多 | ||||||
临床4期 | 22 | Placebo (Placebo) | 壓夢鏇獵襯鹽觸膚鑰簾(顧構憲簾鏇蓋襯範構選) = 醖餘鏇蓋鹹願觸網襯鹹 鹽淵願鹽範夢鏇淵鹹淵 (鹹餘蓋衊製窪願鹹鹽顧, 53.03) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 壓夢鏇獵襯鹽觸膚鑰簾(顧構憲簾鏇蓋襯範構選) = 獵製齋醖齋鬱夢獵醖製 鹽淵願鹽範夢鏇淵鹹淵 (鹹餘蓋衊製窪願鹹鹽顧, 54.22) 更多 | ||||||
N/A | - | EP-104GI 4 mg total dose | 衊艱製製簾鹽鏇壓鏇繭(壓窪網艱簾膚廠醖鹹範) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. 鹹衊糧選願餘襯糧願鏇 (膚廠壓簾鬱膚構艱蓋糧 ) | - | 2024-10-13 | ||
EP-104GI 8 mg total dose |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用